5BA Clinical validation of in vitro drug sensitivity microarray data: regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00-01)

H.Bonnefoi; A.Potti; L.Mauriac; M.Tubiana-Hulin; M.Campone; D.Cameron; J.Bergh; M.Delorenzi; J.R.Nevins; R.Iggo

首页> 外文期刊>European Journal of Cancer Supplements >5BA Clinical validation of in vitro drug sensitivity microarray data: regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00-01)

【24h】

5BA Clinical validation of in vitro drug sensitivity microarray data: regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00-01)

机译：5BA体外药物敏感性微阵列数据的临床验证：在一项随机试验中，特定于治疗方案的签名可预测乳腺癌对新辅助化疗的病理完全反应（EORTC 10994 / BIG 00-01）

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第6期|共1页
作者
H.Bonnefoi; A.Potti; L.Mauriac; M.Tubiana-Hulin; M.Campone; D.Cameron; J.Bergh; M.Delorenzi; J.R.Nevins; R.Iggo;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. Clinical validation of in vitro drug sensitivity microarray data: regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00-01) [J] . H. Bonnefoi, A. Potti, L. Mauriac, European Journal of Cancer Supplements . 2007,第6期

机译：体外药物敏感性微阵列数据的临床验证：一项随机试验（EORTC 10994 / BIG 00-01）中，特定于治疗方案的签名预测了乳腺癌对新辅助化疗的病理完全反应
2. Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. [J] . Bonnefoi H, Potti A, Delorenzi M, The lancet oncology . 2011,第2期

机译：撤回-预测乳腺癌对新辅助化疗反应的基因签名的验证：EORTC 10994 / BIG 00-01临床试验的一项子研究。
3. Expression of concern--validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. [J] . Collingridge D The lancet oncology . 2010,第9期

机译：关注的表达-预测乳腺癌对新辅助化疗反应的基因签名的验证：EORTC 10994 / BIG 00-01临床试验的一项子研究。
4. Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using Deep Learning with Integrative Imaging, Molecular and Demographic Data [C] . Hongyi Duanmu, Pauline Boning Huang, Srinidhi Brahmavar, International Conference on Medical Image Computing and Computer-Assisted Intervention . 2020

机译：利用综合成像，分子和人口统计数据预测对乳腺癌新辅助化疗的病理完全反应
5. Development and Validation of a Nomogram to Predict Pathological Complete Response to Neoadjuvant Chemotherapy for Breast Cancer. [D] . Yang, Victoria Qi. 2015

机译：诺法图的开发和验证，以预测对乳腺癌新辅助化学疗法的病理完全反应。
6. Editors choice: Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial [O] . H. Bonnefoi, S. Litière, M. Piccart, -1

机译：编辑选择：新辅助化疗后的病理完全缓解是独立的预测因素与简化的乳腺癌固有亚型无关：EORTC 10994 / BIG 1-00 III期试验的标志性和两步法分析
7. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial [O] . Bonnefoi, H., Litière, S., Piccart, M., 2017

机译：新辅助化疗后的病理完全缓解是独立的预测因素，与简化的乳腺癌固有亚型无关：EORTC 10994 / BIG 1-00 III期试验的标志性和两步法分析

5BA Clinical validation of in vitro drug sensitivity microarray data: regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00-01)

著录项

相似文献

相关主题

期刊订阅